Government Enforcement and Litigation
At Haynes and Boone, our national Government Enforcement and Litigation Practice Group knows that when companies – or their executives and directors – face significant potential criminal or civil liability, they need lawyers who understand how prosecutors and regulators think.
Our team includes former high-ranking federal prosecutors and longtime enforcement defense lawyers experienced at resolving the most sensitive matters through thorough investigation and skillful negotiation.
When issues arise at a company, we understand the benefit of timely resolution. Our team quickly delivers the knowledge and resources needed to undertake complex and time-pressured internal investigations that often accompany corresponding governmental investigation or civil claims. Providing a coordinated and consistent defense in the face of such parallel proceedings has been the hallmark of our practice for decades.
Our experience includes defending companies and individuals in cases involving:
- Antitrust violations
- Environmental compliance and reporting violations
- False Claims Act and Qui Tam/whistleblower proceedings
- Foreign Corrupt Practices Act violations
- Government contracting and procurement fraud
- Healthcare fraud and abuse
- International trade and customs fraud
- Mail and wire fraud
- Money laundering violations
- RICO violations
- Securities law violations
In light of ever-increasing regulation, we also routinely counsel clients on establishing corporate compliance programs. Our lawyers are skilled in developing tailored compliance programs to meet the demands of a client’s industry or particular needs, whether to minimize risk of misconduct or in response to previous problems.
From the outset of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) engaged in policymaking at a blistering speed compared to its historically measured pace. Robert Califf, who previously led the agency under Obama, was recently confirmed as FDA commissioner, and Califf’s approach to agency guidance will be closely monitored by many stakeholders. With two COVID-19 [...]